DSEY vs SBTX

Diversey Holdings Ltd.

Diversey Holdings, Ltd., through its subsidiaries, provides infection prevention and cleaning solutions in Europe, North America, Latin America, the Asia Pacific, the Middle East, and Africa. It operates through two segments, Institutional, and Food and Beverage. The company manufactures, markets, and sells infection prevention and personal care products; floor and building care chemicals; kitchen and mechanical ware wash chemicals, and machines; dosing and dispensing equipment; and floor care machines to healthcare, education, food service, retail and grocery, hospitality, and building service contractor industries. It also provides a range of engineering, consulting, and training services related to productivity management, water and energy management, and risk management. In addition, the company offers chemical products; engineering and equipment solutions; training; and knowledge-based services, as well as water treatment services to brewing, beverage, dairy, processed foods, pharmaceutical, and agriculture industries. Diversey Holdings, Ltd. was founded in 1923 and is headquartered in Northampton, United Kingdom.

Silverback Therapeutics Inc.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.